IL1B and Down syndrome: The use of IL-1β inhibitors has been limited due to cost effectiveness (expensive therapy in a self-limited syndrome), difficulties in administration (painful subcutaneous injections), possibility of immunosuppression, and the parents’ resistance to consent to the administration of the therapy [1].